Research To Practice | Oncology Videos

Featuring perspectives from Dr Elizabeth O'Donnell, including the following topics: Introduction: Quality of Life in Multiple Myeloma (0:00) CAR (Chimeric Antigen Receptor) T-Cell Therapy (9:29) Bispecific Antibodies (33:08) Belantamab Mafodotin (43:11) CME information and select publications

Featuring a slide presentation and related discussion from Dr Rachna Shroff, including the following topics: Colorectal Cancer (0:00) Gastroesophageal Cancers (19:20) Hepatocellular Carcinoma (27:20) Biliary Tract Cancers (37:59) Pancreatic Cancer (41:33) CME information and select publications

Featuring an interview with Dr Rachna Shroff, including the following topics: Novel targets and emerging strategies for the treatment of pancreatic cancer (0:00) Current and emerging approaches to the care of patients with biliary tract cancers (6:28) Efficacy and tolerability of approved and investigational therapies for hepatocellular carcinoma ()18:42) Incorporating immuno-oncology agents and targeted strategies into the care of patients with gastroesophageal cancer (28:07) Evaluating current and emerging targeted approaches to the treatment of colorectal cancer (35:28) CME information and select publications

Featuring perspectives from Dr Matthew Smith, including the following topics: Introduction: Abemaciclib for Prostate Cancer? (0:00) Case: A man in his early 70s with a PSA of 150 ng/mL, Gleason 4 + 4 and upper abdominal adenopathy — Jennifer L Dallas, MD (9:30) Case: A man in his late 60s with Gleason 4 + 4, PSA of 147 ng/mL and a negative CT — David S Morris, MD (34:30) Case: A man in his late 60s with coronary artery disease and Gleason 4 + 4 who underwent external beam radiation therapy (EBRT) in 2013 and now has increasing PSA of 3.8 with a 6-month doubling time — Gurveen Kaur, MD (37:56) Case: A man in his mid 60s who experiences M0 progression after EBRT followed by androgen deprivation therapy (ADT) but refuses to continue ADT — Henna Malik, MD (41:44) Case: A man in his early 50s with a slowly rising PSA (now 1.31) after radical prostatectomy and salvage radiation therapy; PSMA PET scan denied by insurance, now appealed — Kapisthalam (KS) Kumar, MD (50:23) Case: A man in his late 70s with Gleason 5 + 4 and a PSA of 23 ng/mL increasing after EBRT followed by ADT, cryoablation and enzalutamide; after a response, 18F-fluciclovine PET shows subtle focus of uptake in left prostate — Susmitha Apuri, MD (57:06) CME information and select publications

Featuring perspectives from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda, including the following topics: Front-Line Chronic Lymphocytic Leukemia (CLL; Standard-Risk Patients) — Anthony R Mato, MD, MSCE (0:00) CLL in 2022: Front-Line Therapy for Patients with High-Risk Disease — Danielle Brander, MD (28:50) Fixed-Duration Targeted Therapy for CLL — William G Wierda, MD, PhD (59:26) Novel Investigational Agents and Strategies for CLL — Matthew S Davids, MD, MMSc (1:13:11) CME information and select publications

Featuring a slide presentation and related discussion from Dr Rebecca Heist, including the following topics: Targeting MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) (0:00) Efficacy and tolerability of MET tyrosine kinase inhibitors in patients with NSCLC and MET alterations (12:35) Mechanisms of resistance to therapies for MET-altered NSCLC (19:11) Evaluating the role of antibody-based therapy in the treatment of MET-altered NSCLC  (25:17) CME information and select publications  

Featuring an interview with Dr Rebecca Heist, including the following topics: Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00) Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27) Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24) Managing MET-altered NSCLC in patients with brain metastases (7:55) Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27) Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55) Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation  (24:02) Novel agents and strategies for the management of MET-altered NSCLC (32:00) CME information and select publications

Featuring a slide presentation and related discussion from Dr Brady Stein, including the following topics: Introduction to myelofibrosis (MF) and the use of JAK inhibitors as therapy for MF (0:00) Available efficacy and safety data with ruxolitinib for MF (4:17) Pivotal data leading to the approval of fedratinib (13:11) Unique features of pacritinib and current role in treatment algorithm for MF; other novel therapies under investigation (19:17) CME information and select publications

Featuring an interview with Dr Brady Stein, including the following topics: Case: A man in his late 70s with myelofibrosis (MF) presenting with fatigue and night sweats (0:00) Incidence and severity of fatigue and other symptoms; use of symptom scales to measure severity (3:43) Rapidity of symptom response to ruxolitinib; emerging data with momelotinib (7:34) Novel therapeutic targets for MF: BET, PI3K and BCL2 (13:25) Available data on JAK inhibitors for essential thrombocytosis and polycythemia vera; pathogenesis of pruritus and optimal management (20:31) Clinical pearls on managing splenomegaly, weight loss and other MF symptoms (26:34) Risks of localized therapy for splenomegaly; splenic progression among patients receiving ruxolitinib (30:14) Prevention and management of withdrawal rebound from ruxolitinib; factors to consider in choosing JAK inhibitors for different risk groups (34:17) Myths and misperceptions about MF among community general oncologists (38:26) Management algorithms for transplant-eligible and transplant-ineligible patients (44:32) Current understanding of MF pathophysiology; end-of-life care for patients with MF (50:13) CME information and select publications

Featuring a slide presentation and related discussion from Dr Pamela Kunz, including the following topics: Epidemiology of neuroendocrine tumors (NETs) (0:00) Strategies for the hormonal control of NETs (11:03) Tools for tumor control (17:03) CME information and select publications

Featuring an interview with Dr Pamela Kunz, including the following topics: Increasing incidence of neuroendocrine tumors (NETs); heterogeneity in the clinical presentation of patients with NETs (0:00) Case: A woman in her early 50s newly diagnosed with a metastatic NET; optimal patient workups (5:08) Choosing between observation and treatment for metastatic NETs (9:52) Cardiovascular issues associated with NETs; factors to consider when selecting a somatostatin analogue (14:16) Case: A man in his early 60s with a 5-year history of metastatic small bowel NET; available data with telotristat for carcinoid syndrome diarrhea (21:13) Case: A man in his early 60s with a 2-month history of lower left quadrant cramping, reduced appetite, and weight loss (28:07) Key takeaways about the management of NETs; potential future strategies for treating NETs (33:26) CME information and select publications

Featuring perspectives from Dr Pasi Jänne, including the following topics: Introduction: Journal Club with Pasi A Jänne, MD, PhD — Part 1 (0:00) Case: An Asian man in his late 60s with adenocarcinoma of the lung and pleural effusion with EGFR amplification (PD-L1 20%) — Jennifer L Dallas, MD (12:33) Case: A man in his late 50s with metastatic adenocarcinoma of the lung with discordant EGFR testing results and a new mediastinal lesion after therapy with osimertinib — Rohit Gosain, MD (16:10) Case: A man in his late 40s with metastatic adenocarcinoma of the lung and a brain metastasis with an EGFR exon 19 mutation and disease progression after stereotactic body radiation therapy (SBRT) and osimertinib, now with an ALK mutation by RNA testing (PD-L1 0) — Namrata I Peswani, MD (18:44) Case: A man in his early 50s with Stage III unresectable adenocarcinoma of the lung with an EGFR mutation who receives chemoradiation therapy and consolidation durvalumab, now with metastatic recurrence — Ferdy Santiago, MD (21:51) Case: A man in his early 70s with Stage IIIC large cell neuroendocrine carcinoma of the lung and an EGFR S768I mutation (PD-L1 1%) — Jarushka Naidoo, MB BCH, MHS (28:17) Case: A man in his early 80s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion mutation and disease progression on mobocertinib — Jiaxin (Jason) Niu, MD, PhD (32:15) Case: A woman in her mid 70s with adenocarcinoma of the lung and an EGFR exon 20 insertion mutation with new bone and brain metastases after therapy with osimertinib — Dr Niu (37:11) Journal Club with Dr Jänne — Part 2 (43:02) Case: A woman in her mid 80s with metastatic adenocarcinoma of the lung with an EGFR exon 21 mutation who switched to erlotinib due to osimertinib-related toxicities, now with recurrence at the primary site (PD-L1 10%) — John Yang, MD (55:18) Case: An Asian man in his early 70s with metastatic adenocarcinoma of the lung with an EGFR exon 19 deletion and brain metastases who receives SBRT and osimertinib but develops extracranial biopsy-proven small cell lung cancer progression — Dr Niu (58:35) CME information and select publications

Featuring perspectives from Dr Sagar Lonial, including the following topics: Journal Club with Sagar Lonial, MD — Part 1 (0:00) Case: A man in his late 50s with relapsed t(11;14) multiple myeloma (MM) 17 years after initial induction treatment and ASCT — Rajalaxmi McKenna, MD (16:45) Case: A man in his mid 70s with NDMM receives daratumumab/lenalidomide/dexamethasone in EAA181 clinical trial and develops ileus — Erik Rupard, MD (31:09) Case: A man in his early 80s with NDMM, a borderline performance status and multiple medical comorbidities, including DM, CHF and CKD — Ranju Gupta, MD (35:18) Case: A woman in her late 60s with biochemical progression of del(17p) MM, s/p RVd, ASCT and 1 year of maintenance bortezomib/lenalidomide — Warren S Brenner, MD (38:40) Case: An otherwise healthy man in his mid 70s with refractory MM, s/p 5 prior lines of therapy — Jeremy Lorber, MD (43:36) Faculty Survey (55:05) CME information and select publications

Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics: Emerging data with targeted agents for metastatic melanoma (0:00) Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13) Comparing targeted agents and immune checkpoint inhibitors (17:34) Current melanoma guidelines and other therapies under investigation (24:09)  CME information and select publications

Featuring an interview with Prof Axel Hauschild, including the following topics: Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00) Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23) Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58) Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36) T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23) Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13) Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05) Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25) CME information and select publications

Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics: Prologue (0:00) First-line treatment (3:38) Bispecific antibodies (34:41) CAR T-cell therapy (48:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics: Biology of RET Genetic Alterations in Cancer (0:00) Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44) Mechanisms of Action of Selective RET Inhibitors (3:58) Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04) Updated Efficacy and Safety Results with Pralsetinib Therapy for RET-Altered NSCLC (13:14) Mechanisms of Resistance to Selective RET Inhibitors (19:33) CME information and select publications

Featuring an interview with Dr Justin Gainor, including the following topics: Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00) Significance of non-fusion RET abnormalities in NSCLC (3:33) Clinical impact of tumor-agnostic targeted therapy (5:11) Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46) Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24) Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45) Adjuvant therapy for RET-rearranged NSCLC (26:23) Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07) Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40) Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28) CME information and select publications

Featuring perspectives from Dr Nancy Lin, including the following topics: Introduction: Journal Club with Nancy U Lin, MD (0:00) Case: A woman in her late 60s with ER-positive, HER2-positive breast cancer who has significant neuropathy and develops liver metastases after adjuvant docetaxel/carboplatin/trastuzumab — Laurie Matt-Amaral, MD, MPH (15:30) Case: A woman in her late 80s with weakly ER-positive, PR-negative, HER2-positive, gBRCA2 mutation-positive T2N1M0 breast cancer after neoadjuvant paclitaxel/trastuzumab — Zanetta S Lamar, MD (20:16) Case: A woman in her early 50s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) with progressive brain metastases after T-DM1 and whole braid radiation therapy — Justin Peter Favaro, MD, PhD (31:06) Case: A woman in her late 40s with triple-positive breast cancer after resection of brain metastasis — Shaachi Gupta, MD, MPH (37:26) Case: A woman in her mid 60s with ER/PR-positive, HER2-low mBC after endocrine therapy-based treatments, capecitabine — Vignesh Narayanan, MD (46:44) Case: A woman in her early 60s with progressive triple-positive mBC receiving T-DXd — Joseph Martins, MD (54:36) CME information and select publications

Featuring an interview with Prof Sia Daneshmand, including the following topics: Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00) Alternative induction regimens when BCG is not available (4:06) Treatment options for patients with BCG-refractory disease (8:46) Role of immunotherapy in treating NMIBC (13:58) Role of cystectomy in treating NMIBC (15:47) Intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (20:37) Dispelling myths and misperceptions about cystectomy and counseling eligible patients (26:19) Neoadjuvant and adjuvant therapy for MIBC (37:40) CME information and select publications

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics: Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00) Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26) Emerging data with novel agents and strategies for the management of UBC (14:52) Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57) Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27) Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43) CME information and select publications

Featuring perspectives from Drs Guillermo Garcia-Manero, Gail Roboz and David Sallman, including the following topics: Prologue: A vision for the future (0:00) Classification and prognosis of myelodysplastic syndromes (MDS) (23:34) Current management of lower-risk MDS (25:57) Current management of higher-risk MDS (38:16) MDS-Acute Myeloid Leukemia continuum and overlap: Venetoclax and other targeted therapy (46:38) CME information and select publications

Featuring perspectives from Dr Carl Gay, including the following topics: Introduction: Journal Club with Carl M Gay, MD, PhD (0:00) Case: A woman in her early 60s with extensive-stage small cell lung cancer (ES-SCLC) and a small residual lung mass after carboplatin/etoposide/atezolizumab — Kapisthalam (KS) Kumar, MD (19:15) Case: A woman and heavy smoker in her early 70s who develops widespread ES-SCLC after chemotherapy/radiation therapy for limited-stage SCLC — Neil Morganstein, MD (24:24) Case: A man in his mid 60s with ES-SCLC and disease progression after carboplatin/etoposide/atezolizumab with central nervous system metastases (FGFR1 gain, tumor mutational burden 11 mut/Mb) who receives lurbinectedin/radiation to the brain — Adam R Miller, MD (38:36) Case: A man in his early 60s with progressive ES-SCLC s/p carboplatin/atezolizumab on lurbinectedin with dose adjustment — Rohit Gosain, MD (47:38) Case: A woman and current smoker in her early 70s with ES-SCLC who receives dose-attenuated chemoimmunotherapy due to multiple comorbidities — Minesh Dinubhai Patel, MD (58:09) CME information and select publications

Featuring perspectives from Dr Stephanie Lheureux, including the following topics: Prologue: Seminars in Cancer Biology (0:00) Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54) Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33) Case: A woman in her early 60s with ovarian cancer and prolonged pancytopenia after treatment with a PARP inhibitor — Joseph Martins, MD (38:51) Case: A woman in her mid 60s with platinum-resistant recurrence of BRCA wild-type clear cell ovarian cancer after carboplatin/paclitaxel/bevacizumab and maintenance bevacizumab (homologous recombination deficiency [HRD] negative) — Neil Morganstein, MD (43:21) Case: A woman in her early 60s with multiregimen-recurrent BRCA wild-type, HRD-negative metastatic ovarian cancer — Rahul Gosain, MD (47:44) Case: A woman in her late 60s with recurrent platinum-resistant, BRCA wild-type, HR-proficient ovarian cancer after receiving paclitaxel/tumor treating fields on a clinical trial — Dr Chase (52:07) CME information and select publications

Featuring perspectives from Dr Robert Haddad, including the following topics: ESMO 2022 (0:00) Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39) Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21) Case: An Asian woman in her early 40s who has received cisplatin/radiation therapy and gemcitabine/cisplatin for locoregionally advanced nasopharyngeal cancer develops metastatic disease (PD-L1 CPS 10) — Dr Cohen (31:21) Case: A man in his early 70s presents with recurrent and rapidly progressing HPV-negative metastatic head and neck cancer — Neil Morganstein, MD (38:55) Case: A man in his late 50s who has undergone definitive radiation therapy and surgery for locally recurrent SCC of the head and neck presents with worsening shortness of breath — Mamta Choksi, MD (41:42) Case: A man in his early 70s with a longstanding history of T-cell large granular lymphocytic leukemia presents with metastatic HPV-positive SCC of the left nostril (PD-L1-negative) — Spencer H Bachow, MD (44:50) Case: A man in his late 50s presents with HPV-positive Stage III cancer of the base of the tongue — Dr Cohen (49:03) Case: A man in his early 70s presents with metastatic anaplastic thyroid cancer (PD-L1-positive, mutations in TERT promoter, PT53 and MEN1) — Dr Rupard (52:00) Case: A man in his early 60s presents with metastatic papillary thyroid cancer with a BRAF V600E mutation — Dr Cohen (56:16) CME information and select publications

Featuring a slide presentation and related discussion from Dr Benjamin Levy, including the following topics: Immune checkpoint inhibitors for treatment-naïve extensive-stage small cell lung cancer (ES-SCLC) (0:00) Evaluating the role of lurbinectedin in therapy for SCLC (9:32) Impact of trilaciclib on myelosuppression in patients with ES-SCLC (19:08) Novel treatment strategies for patients with SCLC (22:14) CME information and select publications

Featuring perspectives from Dr Benjamin Levy, including the following topics: Disease biology of and therapeutic strategies for small cell lung cancer (SCLC) (0:00) Current and future management of limited-stage SCLC (3:32) Case: A man in his mid 70s with newly diagnosed SCLC and isolated brain metastases (5:51) Novel therapies for SCLC (21:51) Future directions for lurbinectedin in the treatment of SCLC (25:54) Case: A man in his late 40s with no smoking history diagnosed with adenocarcinoma of the lung with EGFR exon 19, TP53 and RB1 mutations and small cell transformation apparent on repeat biopsy (29:54) Case: A man in his mid 50s with a heavy smoking history diagnosed with SCLC and disease progression after anti-PD-L1 monotherapy (36:25) Expanding immunotherapy options for the treatment of SCLC (41:07) Palliative and supportive services for patients with SCLC (44:21) CME information and select publications

Featuring an interview with Dr Michael Birrer, including the following topics: Prologue (0:00) Multidisciplinary Management of Endometrial Cancer in Copenhagen, Denmark; Boston, Massachusetts and Little Rock, Arkansas (6:17) Subtypes of Endometrial Cancer (12:51) Treatment for Microsatellite Instability-High Endometrial Cancer (16:27) Microsatellite-Stable Endometrial Cancer (37:26) Future Directions in the Treatment of Endometrial Cancer (49:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Amrita Krishnan, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30) BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07) CME information and select publications

Featuring an interview with Dr Amrita Krishnan, including the following topics: Case: A woman in her early 60s who presents with renal failure and receives CyBorD for multiple myeloma (MM) (0:00) Dyspnea associated with carfilzomib; ocular toxicity with belantamab mafodotin (6:26) Efficacy, tolerability and sequencing of belantamab mafodotin for MM; myths and misperceptions (10:33) Case: A man in his early 70s who presents with back pain and compression fractures; efficacy of bispecific antibodies compared to chimeric antigen receptor (CAR) T-cell therapy (17:40) Emerging data with the GPRC5D-targeted bispecific antibody talquetamab; similarities and differences in the pharmacology of BCMA-targeted bispecific antibodies for MM (25:31) Case: A man in his mid 50s who presents with severe back pain and an L5 mass (30:22) Diagnosis and management of cytokine release syndrome, neurotoxicity and infectious complications with CAR T-cell therapy (35:05) Future roles of bispecific antibodies, CAR T-cell therapy and transplantation in the treatment of MM; eligibility criteria for patients to receive CAR T-cell therapy (44:06) CME information and select publications

Featuring an interview with Dr Heather Wakelee, including the following topics: Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00) Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15) Activity of immunotherapy in patients whose tumors are EGFR mutated (10:29) Case: A woman in her mid 70s with EGFR-mutated NSCLC in her right lung (14:49) Case: A woman in her early 60s with a smoking history and a 4-cm right lower lobe lesion (24:17) Case: A man in his mid 50s with a smoking history and a left upper lobe mass with high PD-L1 expression (28:04) Optimal treatment of localized NSCLC in patients who have alterations in RET, BRAF and ALK (33:08) Importance of primary care doctors screening their patients for lung cancer (37:03) CME information and select publications

Featuring a slide presentation and related discussion from Dr Heather Wakelee, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30) BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07) CME information and select publications

Featuring perspectives from Dr Richard Penson, including the following topics: Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00) Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28) Case: A woman in her late 30s with Stage IIC BRCA wild-type HGSOC who undergoes surgery and receives carboplatin/paclitaxel (LOH-negative) — Dana M Chase, MD (24:39) Case: A woman in her early 60s with Stage IIIC HGSOC and a germline BRCA1 mutation who receives IV/IP paclitaxel/cisplatin — Paul DiSilvestro, MD (28:11) Case: A woman in her early 60s with BRCA wild-type, HRD-negative peritoneal cancer who received neoadjuvant and adjuvant carboplatin/paclitaxel and now presents with altered mental status and a cerebellar metastasis — Karim ElSahwi, MD (34:40) Faculty Survey (40:37) Case: A woman in her early 70s with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a germline PALB2 mutation develops breast cancer during maintenance niraparib — Dr Chase (50:02) Case: A woman in her late 60s with Stage IV BRCA wild-type, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab — Priya Rudolph, MD (59:25) CME information and select publications

Featuring perspectives from Dr Mark Pegram, including the following topics: Introduction: Journal Club with Dr Pegram (0:00) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35) Case: A woman in her early 60s with a 1.8-cm triple-positive invasive ductal carcinoma after partial mastectomy/axillary lymph node dissection (9 N+) receives adjuvant TCHP x 6 — Shaachi Gupta, MD, MPH (27:30) Case: A woman in her early 70s with de novo ER-positive, HER2-positive breast cancer develops asymptomatic, bilateral brain metastases on TCHP — Chris Prakash, MD (36:02) Case: A woman in her early 30s with ER/PR-positive, HER2-negative breast cancer after neoadjuvant dose-dense doxorubicin and cyclophosphamide -> paclitaxel and bilateral mastectomy, now with HER2-positive disease on repeat testing — Zanetta S Lamar, MD (46:08) Case: A woman in her mid 40s with triple-negative breast cancer at biopsy declines neoadjuvant therapy and at surgery has a 3.2-cm node-negative, HER2-positive tumor — Alan B Astrow, MD (53:20) CME information and select publications

Featuring perspectives from Dr Lecia Sequist, including the following topics: Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26) Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an “escape lesion” on osimertinib — Priya Rudolph, MD, PhD (24:59) Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45) Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1

Featuring a slide presentation and related discussion from Dr Stephen Ansell, including the following topics: Recent updates in the first-line management of advanced classical Hodgkin lymphoma (0:00) Emerging data with immune checkpoint inhibitors when combined with current treatment strategies (4:40) Current and future management of early-stage disease (9:53) Treatment options for patients with relapsed HL (17:52) Later-line options for patients with multiply-relapsed disease (24:46) CME information and select publications

Featuring perspectives from Dr Stephen Ansell, including the following topics: Evolution of first-line management of advanced Hodgkin lymphoma (HL) (0:00) Transplant strategies and outcomes for patients with relapsed/refractory HL (4:20) Chemoimmunotherapy options for patients with HL (8:06) Current and future management of limited-stage disease (11:52) Addition of antibody-drug conjugates to HL treatment strategies (22:52) Long-term management of HL (29:16) Future management of HL — novel agents and strategies (34:56) CME information and select publications

Featuring a slide presentation and related discussion from Dr Charles Powell, including the following topics: Pathophysiology and clinical features of interstitial lung disease (ILD) associated with anticancer therapies (0:00) Anticancer therapies linked to the development of ILD (5:28) Patterns of ILD presentation and optimal evaluation of suspected ILD; treatment guidelines based on grade of severity (12:21) ILD associated with antibody-drug conjugates (21:06) Answers to common questions about the diagnosis and management of ILD in cancer patients (38:33) Representative cases of ILD associated with anticancer drugs (43:21) CME information and select publications

Featuring an interview with Dr Charles Powell, including the following topics: Role of the pulmonologist in the cancer care team; frequency of fatal and Grade 4 interstitial lung disease (ILD) with antibody-drug conjugates (0:00) Pathophysiology of pneumonitis associated with checkpoint inhibitors versus antibody-drug conjugates; differences in presentation of ILD based on the cause of disease (8:04) Myths and misperceptions about drug-related pneumonitis among general medical oncologists (14:08) Monitoring for the onset of ILD using remote technology; typical time to onset of ILD (21:45) Risk factors for the development of ILD among patients receiving anticancer therapy (25:58) Incidence of ILD with bispecific antibodies; mechanisms underlying differences in the incidence of ILD associated with various antibody-drug conjugates (33:45) CME information and select publications

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: Journal Club (0:00) Case: A woman in her mid 50s with extensive-stage small cell lung cancer (ES-SCLC) who had an excellent response to chemotherapy with immunotherapy (IO) and has been on maintenance IO for 2 years — Adam R Miller, MD (22:05) Case: A woman in her mid 60s with ES-SCLC who presented with superior vena cava syndrome and has a near complete remission with chemo-IO — Namrata I Peswani, MD (28:27) Case: A woman in her late 80s with metastatic SCLC possibly of adrenal origin who has an excellent response to chemo-IO — John Yang, MD (34:14) Case: A woman in her mid 70s with recurrent ES-SCLC who has prolonged disease control on topotecan/trilaciclib — Ferdy Santiago, MD (41:09) Case: A woman in her late 50s with ES-SCLC and brain metastases who responds to chemo-IO but later experiences disease progression (PD) and has toxicity with topotecan — Dr Miller (45:34) Case: A woman in her late 60s with ES-SCLC who has PD on chemo-IO but responds to lurbinectedin with only mild toxicity — Mohamed K Mohamed, MD, PhD (48:28) Case: A man in his early 70s with synchronous Stage III SCLC and Stage I non-small cell lung cancer who receives concurrent chemoradiation therapy — Daniel R Carrizosa, MD, MS (1:00:34) CME information and select publications

Featuring an interview with Dr Mansoor Raza Mirza, including the following topics: Delivery of care models for endometrial cancer (0:00) Molecular profiling and treatment for endometrial cancer (1:57) Current use of immunotherapy for the management of endometrial cancer (8:56) Mitigating and managing immunotherapy-associated adverse events for patients with endometrial cancer (13:40) Immune checkpoint inhibitors for localized endometrial cancer(18:51) Practical considerations in the care of patients with endometrial cancer (22:17) Targeted therapy for patients with endometrial cancer (30:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Mansoor Raza Mirza, including the following topics: Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00) Immunotherapy for mismatch repair-proficient endometrial cancer (9:18) Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11) CME information and select publications